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Abstract: Combining neo-adjuvant chemotherapy and surgery is part of multimodality treatment
of malignant pleural mesothelioma (MPM), but not all patients benefit from this approach. In this
exploratory analysis, we investigated the prognostic value of circulating miR-625-3p and lncRNA
GAS5 after neo-adjuvant chemotherapy. 36 MPM patients from the SAKK 17/04 trial (NCT00334594),
whose blood was available before and after chemotherapy were investigated. RNA was isolated
from plasma and reverse transcribed into cDNA. miR-16-5p and β-actin were used as a reference
gene for miR-625-3p and GAS5, respectively. After exclusion of samples due to hemolysis or RNA
degradation, paired plasma samples from 32 patients before and after chemotherapy were further
analyzed. Quantification of miR-625-3p levels in all 64 samples revealed a bimodal distribution and
cloning and sequencing of miR-625-3p qPCR product revealed the presence of miR-625-3p isomiRs.
Relative change of the circulating miR-625-3p and GAS5 levels after chemotherapy showed that
increased circulating miR-625-3p and decreased GAS5 was significantly associated with disease
progression (Fisher’s test, p = 0.0393). In addition, decreased levels of circulating GAS5 were
significantly associated with shorter overall and progression-free survival. Our exploratory analysis
revealed a potential value of circulating non-coding RNA for selection of patients likely to benefit
from surgery after platinum-based adjuvant chemotherapy.
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1. Introduction
Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleura for which effective
treatments are limited. Platinum-based induction chemotherapy followed by surgery can achieve
prolonged survival [1–3]. The accurate selection of patients who may profit from surgery is crucial
considering the aggressive and mostly fatal nature of the cancer and the morbidity (and mortality),
which may be associated with the surgical intervention. Efforts are ongoing to define objective and
unbiased prognostic scores, which may help for the selection of candidate patients for surgery [4,5].
These algorithms are mainly based on clinical characteristics and the biology of the tumor is only
marginally taken into consideration, if at all. In this sense, tumor biomarkers would be important
because they would permit to integrate information on the biology of the tumor within clinical decisions
algorithms. Ideally, they would allow the recognition of cancer subtypes refractory to treatment for
which aggressive procedures like surgery would be less effective. Biomarkers from the blood would
be best suited for this purpose because they can be accessed easily and repetitively. In recent years
non-coding RNA (ncRNA) have been identified as a novel opportunity for MPM biomarkers with
prognostic as well as predictive potential [6–10]. Further, ncRNA can be detected from the blood [11],
where they can serve as circulating biomarkers for MPM (reviewed in [12]). In our work we intended
to perform an exploratory study to investigate the potential of ncRNA from the blood to help identify
patients who will profit from surgery after platinum-based chemotherapy. To do so we focused on
miR-625-3p, which we had been previously describing as a circulating biomarker in mesothelioma [13]
and GAS5, a long non-coding RNA (lncRNA) that we had functionally characterized in MPM [14].
Additionally, high levels of miR-635-3p are associated with poor response to oxaliplatin in colon
cancer [15] and expression of miR-625-3p induces oxaliplatin resistance in colon cancer cells [16] and
promotes the proliferation of thyroid cancer cells [17]. The GAS5 gene is a so-called host gene for
small nucleolar RNA (snoRNA) and it is encoded at locus 1q25. It has up to 12 exons and 10 box C/D
snoRNAs within its alternative introns together with conserved 5′-terminal oligopyrimidine tract (5′
TOP) [18]. GAS5 is named based on the finding that its expression levels increased upon cell growth
arrest induced after serum starvation [19] or as the result of rapamycin-induced cell cycle arrest [18].
In this study, we have investigated changes in the blood level of miR-625-3p and GAS5 before and after
platinum chemotherapy in a unique cohort of MPM patients treated with neoadjuvant chemotherapy
followed by extrapleural pneumonectomy (EPP) and randomized for radiotherapy [20]. Next, we have
correlated the blood level changes of the two ncRNAs with patients’ survival. Our work provides an
exploratory observation on the prognostic role of miR-625-3p and GAS5 after adjuvant chemotherapy,
which may represent an additional help for the selection of candidate patients for surgery
2. Results
2.1. Plasma Levels of Circulating miR-625-3p and GAS5 in the Cohort of MPM Patients
Circulating miR-625-3p and GAS5 ncRNAs were measured in 36 MPM patients for which plasma
samples were available before and after chemotherapy. The characteristics of patients are summarized
in Table 1. Briefly, 29 patients had epithelioid, 2 had the sarcomatoid, 4 mixed, and 1 had spindle cell
shaped mesothelioma. 33 were male and 3 were female patients.
Non-coding RNA 2019, 5, 41 3 of 12
Table 1. Characteristics of mesothelioma patients.
Variable Total Epithelioid Sarcomatoid Mixed Other
Number 36 29 2 4 1
Age (Mean ± SD) 62.4 ± 5.04 62.5 ± 4.4 61.5 ± 0.7 62.6 ± 2.06 60
Gender (M/F) 33/3 26/3 2/0 4/0 1/0
To normalize miRNA and lncRNA measurements, miR-16-5p [21] and β-actin were used as the
plasma-based reference genes, respectively (Figure S1). Two samples were excluded due to RNA
degradation. The coefficient of variation (CV) of Ct values across the remaining samples was 4.9% for
miR-16-5p and 5.7% for β-actin. The low variation in reference genes demonstrated the stability of the
plasma samples and an equal input amount of plasma-isolated RNA.
We next performed a quality control for cellular contamination, as hemolysis can occur due to
blood processing and affects the miRNA measurement [21]. The levels of the hemolysis specific miRNA
miR-451a and miR-23a-3p were measured. In two samples, Delta Ct difference between miR-23a-3p
and miR-451 (miR-23a–miR-451-3p) was more than five due to hemolysis contamination [22] and we
therefore excluded these samples.
We next assessed the relative levels of circulating miR-625-3p in the remaining 32 pairs of plasma
samples (Figure 1a). MiR-625-3p levels displayed bimodal distribution with 16 patients presenting
relative levels (∆Ct) between 4.61 and 9.28 before and after chemotherapy (miR-625-3plow) and
16 patients with relative levels between −0.07 and −3.95 (miR-625-3phigh) (Figure 1a).
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deter ined by q-PCR in blood collected before and after receiving chemotherapy. Note that higher Ct
value indicates lower expression levels. Two gr ups were defined: miR-625-3phigh (below median of
∆Ct) group and miR-625-3plow group (above median of ∆Ct). (b). Average expression levels of the
major miR-625-3p isomiRs in tumor samples derived from the TCGA MPM cohort. White bars indicate
the tissue levels of the isomiRs, which we also detected in our plasma samples. The nomenclature of
isomiRs indicates the position and number of nucleotides alterations with respect to the archetypes’
sequence. The first number indicates the relative position of the isomiR’s 5′ terminus (F) with respect
to the archetype’s 5′ end; whereas the second number indicates the analogous relationship for the
isomiR’s and the archetypes’s 3′ termini (T). A positive sign (+) indicates that the isomiR’s terminus is
downstream from the archetype terminus (in 5′→3′ direction), while a negative sign (−) indicates that
the isomiR’s terminus is upstream of the archetype’s terminus. Using this notation, miR-625-3p 0F_0T
denotes the archetype miRNA. (c) Relative circulating levels (∆Ct) of GAS5 in blood collected before
and after receiving chemotherapy shows a continuous distribution.
To exclude the possibility that the observed bimodal distribution of circulating miR-625-3p was
due to the cross reactivity and detection of other miRNA species, q-PCR products from 2 samples,
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one which belonged to the miR-625-3phigh (below median of ∆Ct) and another which belonged to the
miR-625-3plow (above median of ∆Ct) group were cloned and sequenced. We found only miR-625-3p
along with isoforms, called isomiRs, which have mostly variations around their 3′ end [23] (Figure S2),
demonstrating that the whole population of miR-625-3p accounts for the observed bimodal distribution.
Interestingly, isomiRs only were detected in the clones derived from the sample in the miR-625-3plow
group, indicating the possibility that in some patients circulating miR-625-3p isomiRs may be more
abundant compared to canonical archetype sequence.
Analysis [24] of an independent cohort of small RNA-seq data derived from mesothelioma
samples from untreated patients generated by The Cancer Genome Atlas (TCGA) not only confirmed
the presence of these miR-625-3p isomiRs detected in circulation (Figure 1b) as well as revealed that
altogether miR-625-3p isomiRs counts are abundant in mesothelioma tissue.
GAS5 levels showed continuous distribution among samples with decreased abundance after
chemotherapy in 9 patients and increase in 22 patients (Figure 1c), while no change was observed
in one patient. Taken together, our results provide evidence that platinum-based chemotherapy can
induce changes in the plasma level of circulating miR-625-3p and GAS5 and that these changes are not
uniform upon treatment but rather specific for each patient.
2.2. Post-Chemotherapy Changes in the Plasma Level of miR-625-3p and GAS5 and Response to Treatment
Next, we were interested in investigating if the changes observed in the plasma levels of circulating
miR-625-3p or GAS5 after platinum-based chemotherapy may associate with treatment response.
The cohort included 24 patients with partial response (PR) or stable disease (SD) after platinum based
neo-adjuvant chemotherapy and 8 patients with progressive disease (PD). Chemotherapy induced
changes in plasma levels of miR-625-3p were not significantly different between the two groups of PD
and PR/SD (p = 0.6851) and showed an average fold increase of 2.7 and decrease of 2.0 (Figure 2a).
After treatment, the levels of miR-625-3p were increased in the plasma of 11 patients with PR/SD
(45.8% of the PR/SD subgroup) and in 5 patients with PD (62.5% of the PD subgroup) and decreased in
13 patients with PR/SD (54.2% of the subgroup) and 3 patients with PD (37.5% of the subgroup).
Changes of GAS5 levels in plasma were not significantly different (p = 0.1845) between the group
of PD and PR/SD (Figure 2b). The average fold change for the increase of GAS5 was 21.5 and for the
decrease it was 4.2. 50% of the patients with PD had an increase and 50% had a decrease of GAS5
plasma levels after chemotherapy (4 patients showed an increase and 4 patients showed a decrease of
GAS5 after treatment). In the subgroup of patients with PR/SD after treatment, we observed an increase
in GAS5 in 18 patients after treatment (75% of the subgroup) and a decrease or no change in 6 patients
(25% of the subgroup). Considering changes in miR-625-3p and GAS5 together, we could observe
that the combination of miR-625-3p increase and GAS5 decrease after chemotherapy was significantly
associated with disease progression (Fisher’s test, p = 0.0393) (Figure 2c). These observations led to
the hypothesis that plasma levels of miR-625-3p and GAS5 may associate with particular biological
subtypes of MPM with different sensitivity to chemotherapy and aggressiveness.
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Figure 2. Increase of circulating miR-625-3p in combination with decrease of circulating GAS5 associates
with disease progression. Relative changes of circulating miR-625-3p (a) and GAS5 (b) before and after
chemotherapy defined patients groups where these circulating nucleic acids displayed increased or
decreased levels. Neither relative changes in miR-625-3p nor in GAS5, was significantly (Fisher’s test)
associated with response to chemotherapy defined as partial response (PR) or stable disease (SD) and
compared to progressive disease (PD). The Tukey box plots of fold change expression have median
values rep esented by the line within the boxes and the lower and upper limit of the boxe denote
the 25th and 75th perce tile while dots represent outliers (c). Combined increasing circulating levels
of miR-625-3p and decreasing circulating levels of GAS5 were significantly (p = 0.0393, Fisher’s test)
associated with the progressive disease (PD) after chemotherapy.
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2.3. Decrease in Circulating GAS5 Associates with Shorter Progression-Free and Overall Survival
Finally, we were interested in investigating if variations of circulating miR-625-3p and GAS5 after
chemotherapy may have a prognostic value as suggested from our observations above. We therefore
investigated survival in the subgroups of patient with miR-625-3p low or high and in the subgroups of
patients with GAS5 low or high. For the subgroups of miR-625-3p we could not observe any significant
differences in overall or progression free survival between patients with low versus high miR-625-3p
levels. Focusing on GAS5 instead, we observed that patients with decreased levels of GAS5 after
chemotherapy had a median overall survival of 7.8 months which was significantly shorter than median
overall survival of patients with GAS5 increase (11.8 months, p = 0.0308, Figure 3a). Also, progression
free survival was significantly shorter for patients with decreased GAS5 after chemotherapy (p = 0.0096,
Figure 3b). These results provided additional evidence for the prognostic role in particular of GAS5 in
MPM after chemotherapy treatment.
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3. Discussion
In this study, we explore miR-625-3p and GAS5 as circulating biomarkers for predicting treatment
outcome for MPM patients undergoing neo-adjuvant chemotherapy and surgery. We observed that
increased levels of miR-625-3p together with decreased levels of GAS5 after platinum doublets were
more frequent in the plasma of patients who were refractory to chemotherapy. Our results in blood
reflected similar recent observations from the TCGA consortium in MPM tissue where low levels
of miR-625-3p and high levels of GAS5 were associated with a better clinical outcome [25]. In the
TCGA dataset miR-625-3p expression positively correlated with a signature of epithelial-mesenchymal
transition (R = 0.32, p= 0.0049, FDR0.0232) [25]. Epithelial to mesenchymal transition could contribute at
least in part, to the chemo-resistance observed in MPM patients with increased levels of miR-625-3p after
chemotherapy. GAS5 is involved in growth control and apoptosis and its expression is predominantly
identified in quiescent MPM tumor cells [14,26]. Reduced levels of GAS5 transcripts are reported
to be indicative of poor prognosis in several types of cancer [26–29]. In accord, in our study overall
survival and progression free intervals were significantly shorter for patients with decreased plasma
levels of GAS5 after neoadjuvant chemotherapy. Based on our observation, both miR-625-3p and GAS5
may represent interesting blood-based biomarkers for clinical decisions. The associations of the two
ncRNAs with response to treatment after chemotherapy could help in the differentiation of responders
from non-responders, and if integrated within the radiological monitoring of MPM patients, it may aid
to the selection of the best suited surgery approaches. Also, considering that changes in levels of GAS5
may predict outcome after chemotherapy and surgery, it may hold potential in guiding treatment
decisions. If integrated within the current clinical decisions tree, it may help to identify in particular
those patients with an expected poor outcome after therapy and for whom aggressive treatments will
be less beneficial. We have to acknowledge here that our observations are based only on a limited
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number of patients. The size of our cohort was dictated by the discovery and hypothesis generating
intent of our investigation. We believe that further validation in an independent next clinical study on
larger number of samples would be highly relevant for the clinical practice of MPM. Ideally, we would
extend our cohort to include patients treated with EPP but also pleural decortication, in order to assess
the biomarkers predicted outcome for different surgical strategies.
Intriguingly, we observed a bimodal distribution for miR-625-3p. Molecular profiles with bimodal
gene expression have consequences for biomarker discovery since they allow setting up a cutoff
and have been used in tissues and circulating tumor cells [30–32]. Bimodal distributions of other
circulating miRs have already been observed in other pathological conditions, such as myelodisplatic
syndrome [33]. However, it had not been observed in a previous study in mesothelioma where we used
stem-loop methodology to detect miR-625-3p [13]. Therefore, the bimodal distribution observed is
possibly linked to the method of detection applied in this study, which is able to detect a larger number
of isomiRs [34]. IsomiRs profiles are able to categorize individuals based on characteristics, such as
sex, race, and population [35] and can distinguish amongst tissue types and disease subtypes [36,37].
It has been estimated that only 8% of the miRNA isoforms present in serum are the canonical miRNA
form [38]. IsomiRs with shifts on their 5′ end alters the miRNA seed sequence, resulting in changes
in target profiles that can target largely non-overlapping groups of mRNAs [39], however, while
the existence of 5′ variant of miR-625-3p has already been described in MPM tissue [40], we found
circulating 3′ variants in the few clones sequenced. 3′ end modifications modulate miRNA processing,
stability, argonaute loading and targeting effectiveness [41–44]. The isomiRs that we identified are also
present in MPM tissue and we describe that miR-625-3p isomiRs are altogether more abundant than
their canonical counterpart. Future studies focused on a more in depth analysis of circulating miR-625
isomiRs will be required to better understand their functions, which are not yet fully understood.
In summary, this exploratory study demonstrates the feasibility of investigating circulating
non-coding RNA in liquid biopsies. We observed that changes in levels of circulating miR-625-3p
and GAS5 associated with response to platinum-based chemotherapy and predicted outcome after
neo-adjuvant treatment and surgery in MPM. These novel blood-based biomarkers may be helpful for
clinical treatment decisions in MPM.
4. Materials and Methods
4.1. Blood Collection and Preparation of Plasma
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of the Zurich University Hospital (KEK-StV-Nr. 24/05). Venous
blood was collected in 10 mL Vacutainer Plus tubes with K2EDTA additive (BD Biosciences) from
36 mesothelioma patients that were enrolled in the trial SAKK 17/04 (NCT00334594) [20]. Blood
samples from MPM patients were collected before and after chemotherapy treatment. Within 1 h of
collection, the blood was centrifuged in the original vials for 10 min at 3000 rpm (approx. 1600 x g)
at room temperature. Plasma was carefully transferred to a new 15 mL non-pyrogenic Falcon tube
and centrifuged again for 10 min at 3000 rpm at room temperature in order to pellet any residual cells.
Cell-free plasma was then aliquoted to 0.5 mL volumes in 1.5 mL RNase-free Eppendorf tubes and
stored at −80 ◦C for further processing.
4.2. RNA Extraction from Plasma
Total RNA enriched with circulating miRNA was extracted from 200 µL plasma using the
miRNeasy Mini kit (Qiagen, Hilden, Germany) following the manufacturer’s instruction. Plasma
samples were thawed completely on ice and mixed gently by pipetting immediately prior to aliquoting
for RNA isolation and to evenly disperse any particulates present. 5 volumes of QIAzol Lysis Reagent
was added followed by vortexing for dissociation of nucleoprotein complexes and 5 min incubation at
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room temperature. One µg MS2 carrier RNA (Roche, Basel, Switzerland) was added before addition of
1 volume of chloroform, followed by vigorously vortexing and centrifugation for 15 min at 12,000× g
at 4 ◦C for subsequent phase separation. The upper aqueous phase containing total RNA was carefully
transferred to a new collection tube, and 1.5 volume of 100% ethanol was added. The sample was
passed through the RNeasy Mini spin column and purified by several washing steps. In order to
obtain a maximum yield, the RNA was eluted from the spin column using two subsequent RNase-free
water aliquots (30 µL each), and stored at −80 ◦C for further processing. To control for extraction
efficacy, synthetic, non-human C. elegans miR-39-3p mimic (Qiagen) was introduced in amount of
2.8 × 108 copies to plasma samples after the addition of the QIAzol Lysis Reagent. This mimic went
through the entire RNA isolation process and was ultimately measured by RT-qPCR in the final
RNA eluate, providing an internal control of technical variations between samples. The coefficient of
variation was 2.7%.
4.3. Reverse Transcription of miRNA and qRT-PCR Measurement
The reverse transcription of miRNAs isolated from plasma was performed using miScript II
RT Kit (Qiagen) using 5 µL of total RNA. In the Qiagen’s miScript system, all mature miRNAs are
polyadenylated by poly(A) polymerase and reverse transcribed into cDNA library using oligo-dT
primers. The oligo-dT primers have a 3′ degenerate anchor and a universal tag sequence on the 5’
end, allowing amplification and detection of multiple mature miRNAs in the real-time PCR step. In
our study the cDNA synthesis was performed using the miScript HiSpecBuffer (for mature miRNA
detection only) and 5 µL of the RNA isolated from plasma was used in a total reaction volume of 20 µL
at the following temperature conditions: 60 min at 37 ◦C followed by 5 min in 95 ◦C. After reverse
transcription, the cDNA was diluted into 1:20 ratio. Obtained cDNA was used immediately in qPCR
reactions or stored at −20 ◦C for further use within 1 week. To perform qPCR, 3 µL was used from
diluted cDNA in a total reaction volume of 10 µL which was set up in triplicates. Amplification was
performed using specific miScript Primer Assays specific for each miRNA (Table S1) together with
miScript SYBR GreenPCR Kit (Qiagen) according to manufacturer’s instruction. Since hemolysis can
happen during plasma preparation and affect the quantification of circulating miRNA, we measured
plasma levels of miR-451-3p and miR-23a as hemolysis indicators [22]. Samples which had ∆Ct
(miR-23a – miR-451-3p) more than 5 Ct cycles were excluded as samples contamination induced
by hemolysis.
5 µL of total RNA was taken to prepare cDNA using Qiagen QuantiTect® Reverse Transcription.
cDNA was amplified using Power SYBR Green PCR Master Mix (Life technologies 4367659)
and gene specific primers for GAS5 [14] and β-actin 5′ GGACCTGACTGACTACCTCAT and
5′-CGTAGCACAGCTTCTCCTTAAT-3′. β-actin was selected as normalizer for circulating lncRNA
because it has been used in other cancer related studies [45,46] and seems relatively stable compared to
non-uniform expression pattern of Sno [38] or rRNA [47]. Relative mRNA levels (∆Ct values) were
determined by comparing the PCR cycle thresholds (Ct) between GAS5 and reference gene β-actin.
The relative change in the circulating levels of miR-625-3p or GAS5 (∆∆Ct) was calculated as following:
∆Ct after chemotherapy − ∆Ct before chemotherapy. Based on the relative change, the patient cohort was
stratified as miR-625-3pincrease or miR-625-3pdecrease, and GAS5increase or GAS5decrease. Increase was
defined as a relative change ∆∆Ct < 0 whereas decrease was defined for those that have ∆∆Ct > 0.
For all q-PCR “No-template” samples were included as negative controls. The qPCR reactions
were set up manually and run on the 7500 Fast Real-Time PCR System thermal cycler (Applied
Biosystems, ThermoFisher Scientific, Reinach, Switzerland) and determined using the 7500 Software
2.0.4 (Applied Biosystems). The specificity of all the q-PCR products was verified by dissociation
curves and by running on 4% agarose gel.
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4.4. TA Cloning
For cloning and sequencing of q-PCR obtained miR-625-3p products, TA cloning technique
was performed using pCR4-TOPO vector (Invitrogen, 450030, ThermoFisher Scientific, Reinach,
Switzerland). To set up a TOPO-TA cloning reaction, the following reagents were mixed: Fresh 1 µL
q-PCR product, 1 µL salt solution (1.2 M NaCl, 0.06 M MgCl2), 1 µL pCR4-TOPO vector, 3 µL water,
and incubated 30 min at room temperature. For positive selection, ccdB screen approach was used.
Briefly, bacteria NEB10-β (New England BioLabs C3019l, Ipswich, MA, USA) were transformed with
2 µL of TOPO-TA cloning reaction and plated on LB-ampicillin plates after which single colonies were
picked and DNA plasmids were extracted. Isolated DNA plasmids were sequenced using either T7 or
M13 primers.
4.5. miR-625 isomiR Detection in Mesothelioma Samples from TCGA
Small RNA sequencing data from a cohort of 87 MPM samples processed by The Cancer Genome
Atlas (TCGA) were obtained through the Genomic Data Commons (GDC) (https://portal.gdc.cancer.gov/
legacy-archive/search/f, dbgap Project ID: 6208). All small RNA sequencing data that had been generated
using the Illumina HiSeq2000 platform was processed according to a previously described pipeline [48,49].
Briefly, aligned sequencing reads (.bam files) retrieved from GDC were converted to unaligned reads
(.fastq files) and trimmed based on Phred quality scores (≥20). Trimmed unaligned reads were then
submitted to the online platform miRMaster (https://ccb-compute.cs.uni-saarland.de/mirmaster) [50].
This platform aligns the reads to the newest version of the human genome (hg38) using the Bowtie
aligner and quantifies miRNA precursors annotated in miRBase v.21, while allowing for one nucleotide
mismatch (http://www.mirbase.org/) [51]. The isomiRs detection performed by miRMaster relies on
the mapping of sequencing reads to annotated miRNA precursors while allowing for up to two 5′/3′
additions and one mismatch in between. Up to two nucleotide variations at the 5′ end and up to five at
the 3′ end are also allowed. Finally, all read counts were normalized to reads per million (RPM).
4.6. Statistical Analysis
All statistical analyses were performed using the GraphPad Prism 5 software (GraphPad Software,
Inc, San Diego, CA, USA). Error bars represent standard deviation of the mean. Correlation degree
between basal levels of circulating miR-625-3p and GAS5 levels was determined by Pearson’s
correlation analysis. Statistical analysis of Kaplan–Meier curve was performed using Log-rank
test. The difference between two response groups PD (progressive disease) and PR/SD (partial
response/stable disease) was analyzed by Fisher’s exact test (two-sided). All p that were < 0.05 were
considered as statistically significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/2311-553X/5/2/41/s1,
Figure S1: Ct (cycle threshold) values of two reference genes miR-16-5p and β-actin in 64 plasma samples
measured by q-PCR. Figure S2: Cloning of q-PCR product confirms miR-625 identity and provides evidence for
isomiRs. Table S1: MiR assays used.
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